Adrenocortical Carcinoma Market Poised for 4% Growth, Set to Hit $3.09 Billion by 2029

How Is the Adrenocortical Carcinoma Market Projected to Grow, and What Is Its Market Size?_x000D_
In recent years, the market size for adrenocortical carcinoma has seen a consistent growth. The market is expected to expand from $3.60 billion in 2024 to $3.77 billion in 2025, with a compound annual growth rate (CAGR) of 4.8%. Factors contributing to the growth during the historic period include increased instances of adrenocortical carcinoma, heightened awareness of rare endocrine tumors, additional government and research funds, burgeoning patient advocacy groups and support, as well as an uptick in the prevalence of rare cancers._x000D_
_x000D_
Expectations are for steady growth in the adrenocortical carcinoma market size over the next few years. The market is predicted to expand to $4.47 billion in 2029, with a compound annual growth rate (CAGR) of 4.4%. The predicted growth in this period is linked to the heightened use of combination therapies alongside a growing acceptance of personalized medicine strategies. This growth is also influenced by an expansion in clinical trials, participation increase in international research networks, and increased government and research funding. Noteworthy trends projected in the forecast period cover advancements in genomic sequencing and personalized medicine, new targeted therapy techniques, progress in immunotherapy, liquid biopsy technology enhancements, and advancement in biomarker identification._x000D_
_x000D_
What Are the Key Drivers Behind the Growth of the Adrenocortical Carcinoma Market?_x000D_
The rise in the occurrence rates of rare cancers, such as adrenocortical carcinoma, is predicted to fuel the market growth for this type of cancer. Rare cancers are characterized by their low incidence rates and considerable impact on patient outcomes, necessitating specialized methods for diagnosis and treatment. The rise in incidence rates of rare cancers is stimulated by several elements, including advancements in diagnostic techniques that have improved the detection of adrenocortical carcinoma. This allows for early identification of cases that might have otherwise been missed earlier. Adrenocortical carcinoma, a rare yet aggressive type of cancer, underscores the need for improved detection and treatment methods and contributes to the rising incidence rates of rare cancers. For example, a report by the International Agency for Research on Cancer of the World Health Organization based in Switzerland stated in February 2022 that nearly six new cases of rare cancers are diagnosed per 100,000 people in the US every year. Consequently, the rising incidence rates of rare cancers are projected to accelerate the adrenocortical carcinoma market's growth._x000D_
_x000D_
Get Your Free Sample Now - Explore Exclusive Market Insights:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=20705&type=smp_x000D_
_x000D_
Who Are the Major Industry Players Fueling Adrenocortical Carcinoma Market Expansion?_x000D_
Major companies operating in the adrenocortical carcinoma market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., Millendo Therapeutics Inc._x000D_
_x000D_
Which Key Developments Are Influencing the Adrenocortical Carcinoma Market?_x000D_
Major players in the adrenocortical carcinoma market, such as Orphagen Pharmaceuticals, Inc., are pivoting towards the creation of innovative treatments like small-molecule drugs, which are prototype therapies that specifically target tumor pathways. These drugs are compact compounds with low molecular weight that can infiltrate cells and target specific proteins or enzymes. By doing this, they control biological processes and act to treat diseases like adrenocortical carcinoma through inhibition of tumor growth pathways. So in January 2023, Orphagen announced that its investigational drug, OR-449, which seeks to treat pediatric adrenocortical carcinoma (a rare, aggressive cancer majorly affecting kids), had received Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA). This cancer often manifests symptoms associated with hormone overproduction, such as virilization and Cushing syndrome. Diagnosis processes involve imaging and hormone evaluations, and factors like age at diagnosis and the possibility of removing the tumor influence the prognosis._x000D_
_x000D_
How Is the Segmentation of the Adrenocortical Carcinoma Market Defined?_x000D_
The adrenocortical carcinoma market covered in this report is segmented -_x000D_
_x000D_
1) By Type: Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma_x000D_
2) By Therapy: Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, External Beam Radiation Therapy, Bratchytherapy, Adjuvant Therapy, Other Therapy_x000D_
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Cancer Research Institutes_x000D_
_x000D_
Subsegments:_x000D_
1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma, Advanced Localized Adrenocortical Carcinoma_x000D_
2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs, Local Regional Metastasis_x000D_
_x000D_
Pre-Book Your Report Now For A Swift Delivery:_x000D_
https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report_x000D_
_x000D_
What Is the Leading Region in the Adrenocortical Carcinoma Market?_x000D_
North America was the largest region in the adrenocortical carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenocortical carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
What Is Covered In The Adrenocortical Carcinoma Global Market Report?_x000D_
_x000D_
- Market Size Analysis: Analyze the adrenocortical carcinoma Market size by key regions, countries, product types, and applications._x000D_
- Market Segmentation Analysis: Identify various subsegments within the adrenocortical carcinoma Market for effective categorization._x000D_
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape._x000D_
- Growth Trends Analysis: Examine individual growth trends and prospects in the market._x000D_
- Market Contribution: Evaluate contributions of different segments to the overall adrenocortical carcinoma market growth._x000D_
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers._x000D_
- Industry Challenges: Analyze challenges and risks affecting the adrenocortical carcinoma market._x000D_
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market._x000D_
_x000D_
Unlock Exclusive Market Insights - Purchase Your Research Report Now!_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20705_x000D_
_x000D_

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.